American Century Companies Inc. lessened its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 8.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,057 shares of the biopharmaceutical company’s stock after selling 2,435 shares during the period. American Century Companies Inc. owned 0.09% of Intercept Pharmaceuticals worth $2,727,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ICPT. Eagle Asset Management Inc. acquired a new position in Intercept Pharmaceuticals in the fourth quarter valued at $28,792,000. Norges Bank acquired a new stake in shares of Intercept Pharmaceuticals during the fourth quarter worth about $28,428,000. Marshall Wace North America L.P. boosted its stake in shares of Intercept Pharmaceuticals by 591.0% during the third quarter. Marshall Wace North America L.P. now owns 198,305 shares of the biopharmaceutical company’s stock worth $25,058,000 after buying an additional 169,606 shares during the period. Two Sigma Investments LP boosted its stake in shares of Intercept Pharmaceuticals by 38.5% during the fourth quarter. Two Sigma Investments LP now owns 310,187 shares of the biopharmaceutical company’s stock worth $31,264,000 after buying an additional 86,171 shares during the period. Finally, Federated Investors Inc. PA boosted its stake in shares of Intercept Pharmaceuticals by 1,156.8% during the third quarter. Federated Investors Inc. PA now owns 85,025 shares of the biopharmaceutical company’s stock worth $10,744,000 after buying an additional 78,260 shares during the period. Institutional investors own 70.24% of the company’s stock.
In other Intercept Pharmaceuticals news, insider David Shapiro sold 562 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $115.01, for a total value of $64,635.62. Following the completion of the transaction, the insider now directly owns 40,061 shares of the company’s stock, valued at $4,607,415.61. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Srinivas Akkaraju sold 23,438 shares of the stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $128.78, for a total transaction of $3,018,345.64. The disclosure for this sale can be found here. Insiders have sold 30,504 shares of company stock valued at $3,779,947 over the last three months. 4.90% of the stock is currently owned by corporate insiders.
NASDAQ ICPT opened at $92.25 on Tuesday. The stock has a market cap of $2.83 billion, a P/E ratio of -8.49 and a beta of 1.63. Intercept Pharmaceuticals Inc has a 52-week low of $64.50 and a 52-week high of $133.74. The company has a debt-to-equity ratio of 19.41, a current ratio of 4.22 and a quick ratio of 4.22.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.42) by ($0.55). The firm had revenue of $53.30 million for the quarter, compared to analysts’ expectations of $52.53 million. Intercept Pharmaceuticals had a negative return on equity of 592.58% and a negative net margin of 172.39%. The company’s revenue for the quarter was up 41.4% on a year-over-year basis. During the same period in the prior year, the company earned ($4.43) earnings per share. As a group, sell-side analysts predict that Intercept Pharmaceuticals Inc will post -9.1 EPS for the current fiscal year.
Several brokerages have recently weighed in on ICPT. Zacks Investment Research downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 18th. B. Riley set a $169.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday. Wells Fargo & Co increased their target price on shares of Intercept Pharmaceuticals from $99.00 to $104.00 and gave the stock a “market perform” rating in a research note on Friday. UBS Group increased their target price on shares of Intercept Pharmaceuticals to $139.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th. Finally, BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the company. Intercept Pharmaceuticals currently has an average rating of “Buy” and an average price target of $144.05.
COPYRIGHT VIOLATION WARNING: “Intercept Pharmaceuticals Inc (ICPT) Shares Sold by American Century Companies Inc.” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2019/04/16/intercept-pharmaceuticals-inc-icpt-shares-sold-by-american-century-companies-inc.html.
Intercept Pharmaceuticals Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Read More: Do You Need a Fiduciary?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.